New bispecific antibody YKST02 enters human trials for Hard-to-Treat myeloma

NCT ID NCT06574568

Recruiting now Disease control Sponsor: Excyte Biopharma Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study is testing a new drug called YKST02 in 70 people with multiple myeloma that has relapsed or not responded to at least two prior treatments. YKST02 is a bispecific antibody designed to attach to both myeloma cells and immune cells, helping the immune system attack the cancer. The main goals are to check the drug's safety, find the right dose, and get an early look at whether it shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: YKST02 (a bispecific antibody that targets BCMA on myeloma cells and CD3 on immune cells to help the body fight the cancer)
What this could lead to: If this early trial shows YKST02 is safe and effective, it could lead to a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong: This is a very early Phase 1 study with only 70 participants, so the drug may not work or could have serious side effects. It is too soon to know if it will be better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

Affiliated Zhongshan Hospital of Dalian University
RECRUITING

Dalian, Liaoning, 116001, China
Beijing Chao-yang Hospital, Capital Medical University
RECRUITING

Beijing, Beijing Municipality, 100024, China
Beijing Jishuitan Hospital, Capital Medical University
RECRUITING

Beijing, Beijing Municipality, 100035, China
Guangxi Medical University Cancer Hospital
NOT_YET_RECRUITING

Nanning, Guangxi, 530021, China
Harbin Medical University Cancer Hospital
RECRUITING

Harbin, Heilongjiang, 150081, China
Henan Cancer Hospital
NOT_YET_RECRUITING

Zhengzhou, Henan, 450003, China
Shandong Cancer Hospital
NOT_YET_RECRUITING

Jinan, Shandong, 250117, China
Shanxi Cancer hospital
NOT_YET_RECRUITING

Taiyuan, Shanxi, 030013, China
Shunde Hospital of Southern Medical University
RECRUITING

Foshan, Guangdong, 528308, China
Sun Yat-sen Memorial Hospital
NOT_YET_RECRUITING

Guangzhou, Guangdong, 510289, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.